RxDoctor Payments Data

Laura Cappelli, MD

Rheumatology · Baltimore, MDNPI 1225273840

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,797 of the $32,959 with a category attached, or 78.3%. 9 manufacturers reported payments, led by Amgen at 30.4% of the total.

$32,959in general payments, 2019–2025

Across 22 payments — averaging $1498.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • AbbVie$6K
  • Pfizer$6K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Sanofi$4K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $428 from 3 others
$45,852in research payments, 2019–2025

Across 44 payments — averaging $1042.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Kiniksa Pharmaceuticals, Ltd.$29K
  • Kiniksa Pharmaceuticals International, PLC$10K
  • Pfizer$7K

What the payments were for

  • Consulting fees$25,79778%
  • Speaking & faculty fees$5,87018%
  • Travel & lodging$7442%
  • Food & beverage$5482%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,959 in reported general payments places this provider in the 85th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$30,477
Medicare patients
132
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept14$148,963
Humira(Cf) PenAdalimumab15$127,686
KevzaraSarilumab13$81,426
MethotrexateMethotrexate Sodium115$4,370
Hydroxychloroquine Sulfate36$2,247
Leflunomide32$2,245
Prednisone88$856
Pilocarpine Hcl11$718
Celecoxib27$673
Pregabalin12$639
Diclofenac Sodium14$339
Folic Acid17$178
Meloxicam15$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiKevzara$3,970$81,42613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →